CA3228221A1 - Methods of treating copper metabolism-associated diseases or disorders - Google Patents

Methods of treating copper metabolism-associated diseases or disorders Download PDF

Info

Publication number
CA3228221A1
CA3228221A1 CA3228221A CA3228221A CA3228221A1 CA 3228221 A1 CA3228221 A1 CA 3228221A1 CA 3228221 A CA3228221 A CA 3228221A CA 3228221 A CA3228221 A CA 3228221A CA 3228221 A1 CA3228221 A1 CA 3228221A1
Authority
CA
Canada
Prior art keywords
subject
copper
weeks
treatment
ttm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3228221A
Other languages
English (en)
French (fr)
Inventor
Brian Meltzer
Eugene Scott SWENSON
Wei-jian PAN
Scott Edward Moseley
Ryan PELTO
Adam QUICQUARO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of CA3228221A1 publication Critical patent/CA3228221A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3228221A 2021-08-17 2022-08-17 Methods of treating copper metabolism-associated diseases or disorders Pending CA3228221A1 (en)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US202163234176P 2021-08-17 2021-08-17
US63/234,176 2021-08-17
US202163235098P 2021-08-19 2021-08-19
US63/235,098 2021-08-19
US202163237120P 2021-08-25 2021-08-25
US202163237089P 2021-08-25 2021-08-25
US63/237,089 2021-08-25
US63/237,120 2021-08-25
US202163237506P 2021-08-26 2021-08-26
US63/237,506 2021-08-26
US202163270421P 2021-10-21 2021-10-21
US63/270,421 2021-10-21
US202163281994P 2021-11-22 2021-11-22
US63/281,994 2021-11-22
US202163290599P 2021-12-16 2021-12-16
US63/290,599 2021-12-16
US202163294715P 2021-12-29 2021-12-29
US63/294,715 2021-12-29
US202263322155P 2022-03-21 2022-03-21
US63/322,155 2022-03-21
US202263339307P 2022-05-06 2022-05-06
US63/339,307 2022-05-06
US202263353790P 2022-06-20 2022-06-20
US63/353,790 2022-06-20
PCT/US2022/040663 WO2023023199A1 (en) 2021-08-17 2022-08-17 Methods of treating copper metabolism-associated diseases or disorders

Publications (1)

Publication Number Publication Date
CA3228221A1 true CA3228221A1 (en) 2023-02-23

Family

ID=83271296

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3228221A Pending CA3228221A1 (en) 2021-08-17 2022-08-17 Methods of treating copper metabolism-associated diseases or disorders

Country Status (5)

Country Link
US (1) US20250082674A1 (https=)
EP (1) EP4387631A1 (https=)
JP (1) JP2024532131A (https=)
CA (1) CA3228221A1 (https=)
WO (1) WO2023023199A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023038909A1 (en) * 2021-09-07 2023-03-16 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders
KR20240159714A (ko) * 2023-04-27 2024-11-06 국립해양생물자원관 다중구리 산화효소 활성 도메인의 개량 펩타이드를 포함하는 구리대사 관련 신경계 질환의 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
MX2020006284A (es) * 2017-12-04 2021-04-12 Alexion Pharma Int Operations Unlimited Company Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
US20220334135A1 (en) 2019-09-12 2022-10-20 Alexion Pharmaceuticals, Inc. Methods of measuring copper concentration in biological samples
US20220387370A1 (en) * 2019-11-21 2022-12-08 Alexion Pharmaceuticals, Inc. Methods of reducing neurological damage in wilson disease patients
EP4243806A1 (en) * 2020-11-13 2023-09-20 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders
WO2023038909A1 (en) * 2021-09-07 2023-03-16 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders

Also Published As

Publication number Publication date
JP2024532131A (ja) 2024-09-05
EP4387631A1 (en) 2024-06-26
US20250082674A1 (en) 2025-03-13
WO2023023199A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
US12233088B2 (en) Bis-choline tetrathiomolybdate for treating Wilson Disease
CA3228221A1 (en) Methods of treating copper metabolism-associated diseases or disorders
US11419832B2 (en) Bis-choline tetrathiomolybdate for treating Wilson Disease
Chen et al. Efficacy and tolerability of coenzyme A vs pantethine for the treatment of patients with hyperlipidemia: A randomized, double-blind, multicenter study
Smith Drugs and pharmaceuticals: management of intoxication and antidotes
US20240342127A1 (en) Methods of treating copper metabolism-associated diseases or disorders
WO2024162974A1 (en) Tetrathiomolybdic acid for use in treating copper metabolism-associated diseases or disorders (wilson disease)
CN117835989A (zh) 治疗铜代谢相关疾病或障碍的方法
EP3265075B1 (en) Roneparstat combined therapy of multiple myeloma
Ballester et al. A randomized, open-label, Phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosis
Alonso-Campero et al. Bioequivalence & Bioavailability

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240809

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240809

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240809

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250826